4Bio Capital logo.png
4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
18. November 2024 08:00 ET | 4Bio Capital
Press Release 4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy Company founded by 4BIO Capital and...
4Bio Capital logo.png
4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
18. November 2024 02:00 ET | 4Bio Capital
Press Release 4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy Company founded by 4BIO Capital and...
4Bio Capital logo.png
4BIO Capital Strengthens Investment Team
04. November 2024 08:00 ET | 4Bio Capital
Press Release LONDON, 4 November 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced and emerging therapies sector, announces today the...
4Bio Capital logo.png
4BIO Capital Strengthens Investment Team
04. November 2024 03:00 ET | 4Bio Capital
Press Release LONDON, 4 November 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced and emerging therapies sector, announces today the...
4Bio Capital logo.png
4BIO Capital leads oversubscribed $28.4 million Series A financing of March Biosciences
23. Oktober 2024 08:05 ET | 4Bio Capital
March Bio is rapidly advancing its innovative autologous chimeric antigen receptor T-cell (CAR-T) therapy, MB-105, in development for the treatment of relapsed and refractory CD5 positive T-cell...
hornet logo.png
Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first potential drug intervention for Epstein-Barr Virus (EBV) driven disease
23. Mai 2024 14:00 ET | Hornet Therapeutics
Press Release Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first potential drug intervention for Epstein-Barr Virus (EBV) driven disease 4BIO Capital...
4Bio Capital logo.png
4BIO Capital Strengthens Advisory Board and Investment Team
11. März 2024 10:00 ET | 4Bio Capital
Press Release 4BIO Capital Strengthens Advisory Board and Investment Team Industry veteran and former CEO of Vifor Pharma Abbas Hussain and world leading vectorology expert and LogicBio...
4Bio Capital logo.png
Development Bank of Japan invests in 4BIO Capital’s Ventures III fund
04. Januar 2024 07:00 ET | 4Bio Capital
Press Release Development Bank of Japan invests in 4BIO Capital’s Ventures III fund 4BIO Ventures III targeting $200-300 million to unlock the treatments of the future by investing in advanced...
4Bio Capital logo.png
Development Bank of Japan invests in 4BIO Capital’s Ventures III fund
04. Januar 2024 02:00 ET | 4Bio Capital
Press Release Development Bank of Japan invests in 4BIO Capital’s Ventures III fund 4BIO Ventures III targeting $200-300 million to unlock the treatments of the future by investing in advanced...
4Bio Capital logo.png
4BIO Capital Portfolio Company Ray Therapeutics Closes Oversubscribed $100M Series A Financing to Advance Optogenetic Gene Therapies for Blinding Diseases
16. Mai 2023 08:00 ET | 4Bio Capital
Press Release 4BIO Capital Portfolio Company Ray Therapeutics Closes Oversubscribed $100M Series A Financing to Advance Optogenetic Gene Therapies for Blinding Diseases Series A follows initial seed...